Article Sidebar
Views PDF: 274
ASSOCIATION BETWEEN BRAF V600E MUTATION AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PAPILLARY THYROID CARCINOMA
Main Article Content
Abstract
Objectives: To describe the prevalence of the BRAF V600E mutation and the association between this mutation and clinical characteristics in patients with papillary thyroid carcinoma (PTC). Methods: A retrospective, cross-sectional study was conducted on 135 patients diagnosed with papillary thyroid carcinoma using histopathology and tested for the BRAF V600E mutation at Bach Mai Hospital from August 2021 to March 2022. Results: The prevalence of the BRAF V600E mutation in PTC was 72.1% (98 out of 135 patients). Females predominated with a female-to-male ratio of 3.2:1. The prevalence of the BRAF V600E mutation in age groups was as follows: < 19 years: 33.3%; 20 - 39 years: 70.0%; 40 - 59 years: 73.3%; 60 - 69 years: 81.5%. There were no statistically significant difference in average age, tumor size, capsular invasion, lymph node metastasis, and distant metastasis between two groups of PTC patients with and without the BRAF V600E mutation. Conclusion: The prevalence of the BRAF V600E mutation in patients with PTC is 72.1%. The frequency of the BRAF V600E gene mutation tends to increase with age. Further research is needed to assess the association between the BRAF V600E mutation and patients’ clinical features.
Article Details
Keywords
Thyroid carcinoma, Papillary thyroid carcinoma, PTC, BRAF V600E.
References
2. Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: Its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocrine Journal. 2009; 56(1):89-97.
3. Rashid FA, Munkhdelger J, Fukuoka J, et al. Prevalence of BRAF(V600E) mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg. 2020; 9(5):1878-1900.
4. Mai Trọng Khoa, Phạm Cẩm Phương, Trần Đình Hà và CS. Mối liên hệ giữa đặc điểm dịch tễ học lâm sàng và tình trạng đột biến gen BRAF V600E ở BN ung thư tuyến giáp thể biệt hoá tại Bệnh viện Bạch Mai. Tạp chí Y học Việt Nam. 2018; 471(10):285-292.
5. Nguyễn Thị Lan Hương, Lê Ngọc Hà, Lê Thanh Hướng. Một số đặc điểm lâm sàng, đột biến BRAF-V600E và kết quả phẫu thuật ung thư tuyến giáp biệt hoá kháng 131I. Tạp chí Nghiên cứu Y học. 2021; 137(1):101-110.
6. Czarniecka A, Oczko-Wojciechowska M, Barczyński M. BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 2016; 5(5):495-505.
7. Li C, Lee KC, Schneider EB et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis. J Clin Endocrinol Metab. 2012; 97(12):4559-4570.
8. Govender D, Chetty R. Gene of the month: BRAF. J Clin Pathol. 2012; 65(11):986-988.
9. Yokoyama A, Kakiuchi N, Yoshizato T, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature. 2019; 565(7739):312-317.
10. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013; 309(14):1493-1501.